What To Look Out For In The Latest Eiger Biopharmaceuticals Inc (EIGR) Trial

Eiger Biopharmaceuticals Inc (NASDAQ:EIGR) just announced first dosing in its phase II LIBERTY trial, and markets seem to have turned a blind eye to the development. The company is down a percentage point...... (read more)